Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovest International a subsidiary of Accentia Biopharmaceuticals, has signed a research agreement with the Max Planck Institute for Dynamics of Complex Technical Systems.
Subscribe to our email newsletter
Under the collaboration, the Max Planck Institute will conduct a series of influenza virus growth studies to determine the advantages of Biovest’s proprietary Hollow Fiber Bioreactor Systems for the efficient and cost-effective cell culture manufacture of viral vaccines.
The organizations will also work on optimizing the conditions for efficient virus production and demonstrate large-scale manufacturing potential.
Biovest chief science officer Mark Hirschel said the collaboration with Max Planck would further demonstrate the advantages and viability of hollow fiber perfusion technology as robust, modular and rapid response instrumentation for the large scale production of viral vaccines.
The financial terms of the deal have not been revealed.